Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Innate Pharma SA
IPHA
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.57
-0.008
-0.51%
Últ. Act.: Oct 21, 10:23 AM
$1.58
0.002
0.13%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Comparar
Informe de acciones
Privacy Manager
Innate Pharma Financials
Innate Pharma (IPHA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Earnings Scheduled For September 17, 2026
Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its second quarter. • Innate Pharma (NASDAQ:IPHA) is projected to report quarterly loss at $0.16 per share on revenue of $9.10
Benzinga Insights
PRO
Innate Pharma H1 EPS $(0.24) Misses $(0.16) Estimate, Sales $6.583M Miss $9.100M Estimate
Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 50 percent. This is a 14.29 percent increase over losses of $(0.28) per share from the
Benzinga Newsdesk
Earnings Scheduled For March 26, 2026
Benzinga Insights
PRO
Innate Pharma FY EPS $(0.64) Beats $(0.65) Estimate, Sales $10.483M Beat $7.230M Estimate
Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 1.69 percent increase over losses of $(0.65) per share from the
Benzinga Newsdesk
Earnings Scheduled For September 17, 2025
Benzinga Insights
PRO
Innate Pharma H1 EPS $(0.28) Up From $(0.34) YoY, Sales $5.51M Down From $13.35M YoY
Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.28) per share. This is a 16.76 percent increase over losses of $(0.34) per share from the same period last year. The company reported $5.51 million in sales
Benzinga Newsdesk
